MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Conor C. Lynch(Moffitt Cancer Center), Mitsuru Futakuchi(Nagoya City University), Atsuya Hikosaka(Nagoya City University), Jennifer L. Begtrup(Vanderbilt University), Rakesh K. Singh(Ionis Pharmaceuticals (United States)), Michelle D. Martin, Barbara Fingleton(Vanderbilt University), Noriyasu Kawai(Nagoya City University), Lynn M. Matrisian(Pancreatic Cancer Action Network), Heath B. Acuff(Vanderbilt University), Tracy Vargo-Gogola(Indiana University), Tomoyuki Shirai, Todd E. Peterson(Vanderbilt University)
Cited by 388
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Metalloproteinases and their inhibitors in matrix remodeling
|Trends in Genetics|1990|1.6k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k
The matrix‐degrading metalloproteinases
|BioEssays|1992|1.4k